Navigation Links
AbbVie Reports Second-Quarter 2014 Financial Results
Date:7/25/2014

s into the market many years ago.  The overall market has experienced low-single digit growth, with Synthroid growth outpacing the market, including product pricing trends.Q)What impacted Lupron sales in the second quarter?A)

Global Lupron sales were $186 million, down 5.2 percent on an operational basis.  Lupron continues to hold a leadership position and maintains significant share of the market.  Performance this quarter is roughly in line with our full-year expectations for Lupron, and is also consistent with recent market trends.Q)What impacted Sevoflurane sales in the second quarter?A)

Global Sevoflurane sales were $154 million in the quarter, up 13.9 percent on an operational basis. Performance in the quarter was driven by strong international execution, including key account retention, and underlying volume trends.Q)What impacted Creon sales in the second quarter?A)

U.S. Creon sales were $110 million in the quarter, up 4.1 percent.  Creon maintains its leadership position in the pancreatic enzyme market, where the product continues to capture the vast majority of new prescription starts.  Q)What impacted Synagis sales in the second quarter?A)

Sales of Synagis were $74 million in the second quarter, up 16.3 percent on an operational basis.  Synagis, which protects at-risk infants from severe respiratory disease, is a seasonal product with the majority of sales in the first and fourth quarters of the year.  Growth in the quarter was driven by continued product uptake and strong commercial execution.Q)What impacted Duodopa sales in the second quarter?A)

Sales of Duodopa, our therapy for advanced Parkinson's disease approved in Europe and other international markets, were $56 million, up 24.2 percent on an operational basis this quarter.  Performance in the quarter is in line with recent trends and our full-year outlook for the product.Q)What impacted Dyslipidemia sale
'/>"/>

SOURCE AbbVie
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine technology :

1. AbbVie to Host Second-Quarter Earnings Conference Call
2. AbbVie to Host Fourth-Quarter and Full-Year 2013 Earnings Conference Call
3. AbbVie Demonstrates 96 percent SVR(12) in its Phase III Study of Treatment-Experienced Patients with Genotype 1 Hepatitis C
4. AbbVie Releases First of Six Phase III Results from Investigational All-Oral, Interferon-Free, 12-week Regimen, Showing 96 Percent SVR12 in Genotype 1 Hepatitis C Patients New to Therapy
5. U.S. Gastroenterologists Have Increased Their TNF-alpha Inhibitor Use Since 2012, Especially for AbbVies Humira, as a Result of Its Recent Approval in Ulcerative Colitis
6. Financial Results, New Drug Applications, and Stock Price Movements - Research Report on Endo, Bristol-Myers Squibb, Express Scripts, AbbVie, and Incyte
7. AbbVie Reports Third-Quarter 2013 Financial Results
8. AbbVie Named a Science Top Employer
9. AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver Meeting
10. AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies
11. Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014  Advanced Medical Isotope Corporation ("AMIC") ... in the development of brachytherapy devices and medical ... that it has filed a de novo ... ("FDA") for marketing clearance for its patented Y-90 ... U.S. Food, Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... decision support to healthcare providers for behavioral health ... has secured $30 million in equity financing from ... C. Drosos , President and Chief Executive Officer. ... adoption and development of Assurex Health,s GeneSight ...
(Date:12/24/2014)... SANTA BARBARA, Calif. , Dec. 23, 2014 ... the Junior Doctors, Association of Sierra Leone ... Sierra Leone for the treatment of local ... While a new dedicated Ebola care center was ... Ebola virus, the facility is not available for local Sierra ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2
(Date:12/25/2014)... When head lice hits a home or ... to get rid of it while keeping it from taking ... now have the solution right in their neighborhood: Lice ... Troopers provides full spectrum head lice screening and treatment services ... Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... chronic illnesses can receive effective, less expensive care from a ... to a team of dedicated health care professionals, a new ... ill and need either hospitalization or a trip to the ... home clinic at the University of Texas in Houston versus ...
(Date:12/25/2014)... -- Overeating is common during the holidays, but there are ... says. "Don,t arrive at a party hungry. It may ... be attending a party, but deprivation leads to hunger, and ... Westchester Hospital in Mount Kisco, N.Y., said in a hospital ... day and even to have a snack before attending a ...
(Date:12/25/2014)... Thompson HealthDay Reporter WEDNESDAY, ... in on a "fountain of youth" drug that can delay ... adults, a new study suggests. Seniors received a significant ... targets a genetic signaling pathway linked to aging and immune ... The experimental medication, a version of the drug rapamycin, ...
(Date:12/25/2014)... December 25, 2014 Thousands of transvaginal ... forward in a number of multidistrict litigations currently underway ... Bernstein Liebhard LLP reports. According to an Order issued ... convene a Joint Status Conference in all of the ... have been directed to submit a proposed agenda to ...
Breaking Medicine News(10 mins):Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4
... proportion of patients with advanced cancer and a life ... common cancer screening tests that are unlikely to provide ... 13 issue of JAMA . Cancer ... (PSA) and colonoscopy, evaluate asymptomatic patients for the detection ...
... Goodwin HealthDay Reporter , TUESDAY, Oct. 12 (HealthDay ... transfusions do just as well as those who receive more, ... varies widely among U.S. hospitals. The studies are published ... the American Medical Association . In the first study, ...
... GABLES, FL (October 12, 2010)--Still hampered by workforce shortages ... care to the full extent of their education and ... the arm they need to transform their profession with ... recommending sweeping changes for improving their profession. The report, ...
... By Kathleen Doheny HealthDay Reporter , TUESDAY, Oct. ... cancer care has long been known by researchers, with ... cancer treatments than white patients. "Less well known is ... something else contributing?" said Dr. Rachel Freedman, a medical ...
... of a large Phase-III clinical trial have shown that ... a hard-to-treat group of rare cancers that affect particular ... European Society for Medical Oncology (ESMO), Dr Marianne Pavel ... improved progression-free survival by 5.1 months in patients with ...
... population ages, health care epidemiologist Padma Kaul and cardiologist Paul ... the University of Alberta, want health-care professionals to talk to ... it be at home, in hospital or a palliative care ... recent study, that the majority of heart failure patients pass ...
Cached Medicine News:Health News:Considerable proportion of patients with advanced cancer continue to undergo common cancer screening 2Health News:Considerable proportion of patients with advanced cancer continue to undergo common cancer screening 3Health News:Heart Surgery Patients Do Fine With Fewer Blood Transfusions: Study 2Health News:Heart Surgery Patients Do Fine With Fewer Blood Transfusions: Study 3Health News:National committee releases findings on transforming and improving the nursing profession 2Health News:Insurance, Income Don't Explain 'Race Gap' in Breast Cancer Care 2Health News:Insurance, Income Don't Explain 'Race Gap' in Breast Cancer Care 3Health News:Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors 2Health News:Medical researchers break down costs to care for heart failure patients at the end of life 2
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
The CE marked HF coagulator which meets the highest ISO safety features....
Finesse electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
Medicine Products: